This database contains 1231 studies, archived under the term: "humans"
Click here to filter this large number of results.
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses
Objective: In Alzheimer’s disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items.; Methods: This exploratory analysis focused on the Alzheimer’s Disease Cooperative Study Activities of Daily Living […]
Improved social interaction and increased anterior cingulate metabolism after group reminiscence with reality orientation approach for vascular dementia
Akanuma, Kyoko,
Meguro, Kenichi,
Meguro, Mitsue,
Sasaki, Eriko,
Chiba, Kentaro,
Ishii, Hiroshi,
Tanaka, Naofumi
A group reminiscence approach (GRA) with reality orientation (RO) is widely used as a psychosocial intervention for dementia. Since clinical effectiveness was reported for the intervention, interest has been directed toward areas of the neuronal network that might be being stimulated. We hypothesized that the frontal lobe associated with social interaction was being stimulated. To […]
Spine Surgery under general anesthesia may not increase the risk of Alzheimer’s disease
Background: Volatile anesthetics cause Alzheimer’s disease (AD)-like neuropathology in animals. We determined whether spine surgery under general anesthesia and anesthetic choice contributed to AD development.; Methods: We searched the Clinical Data Repository of the University of Virginia for patients receiving spine surgery from January 1, 1992 to March 1, 2004. Patients with newly-diagnosed AD after […]
Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment
Yamada, Shizuru,
Akishita, Masahiro,
Fukai, Shiho,
Ogawa, Sumito,
Yamaguchi, Kiyoshi,
Matsuyama, Jun,
Kozaki, Koichi,
Toba, Kenji,
Ouchi, Yasuyoshi
Aim: There is little evidence that dehydroepiandrosterone (DHEA) has beneficial effects on physical and psychological functions in older women. We investigated the effect of DHEA supplementation on cognitive function and ADL in older women with cognitive impairment.; Methods: A total of 27 women aged 65-90 years (mean ± standard deviation, 83 ± 6) with mild […]
The effect of telephone support groups on costs of care for veterans with dementia
Wray, Laura O.,
Shulan, Mollie D.,
Toseland, Ronald W.,
Freeman, Kurt E.,
Vásquez, Bob Edward,
Gao, Jian
Purpose: Few studies have addressed the effects of caregiver interventions on the costs of care for the care recipient. This study evaluated the effects of a caregiver education and support group delivered via the telephone on care recipient health care utilization and cost.; Design and Methods: The Telehealth Education Program (TEP) is a manualized program […]
Phenserine efficacy in Alzheimer’s disease
Winblad, Bengt,
Giacobini, Ezio,
Frölich, Lutz,
Friedhoff, Lawrence T.,
Bruinsma, Gosse,
Becker, Robert E.,
Greig, Nigel H.
To gather preliminary evidence in Alzheimer’s disease (AD) for the efficacy of phenserine, a non-competitive acetylcholinesterase inhibitor that has independent modulatory effects on amyloid-β generation, a 12-week comparison of patients receiving phenserine (10 and 15 mg BID) or placebo was conducted under double-blind conditions. Patients who completed 12 weeks of the double-blind before others were […]
The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer’s disease
Wiig, E. H.,
Annas, P.,
Basun, H.,
Andreasen, N.,
Lannfelt, L.,
Zetterberg, H.,
Blennow, K.,
Minthon, L.
Objectives: To explore the longitudinal stability of measures of cognition during treatment with acetylcholinesterase inhibitors (AchEI) in patients with Alzheimer’s disease (AD).; Materials and Methods: Cognitive status was measured in a cohort of 60 patients at 6 months after initiation of treatment with AchEI (baseline) and after an additional 6 months of treatment (endpoint). A […]
Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer’s disease trial
Wessels, Alette M.,
Pollock, Bruce G.,
Anyama, Norbert G.,
Schneider, Lon S.,
Lieberman, Jeffrey A.,
Marder, Stephen R.,
Bies, Robert R.
Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer’s disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Sixty-five subjects from the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer’s Disease Trial that […]
Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes
Weintraub, Daniel,
Rosenberg, Paul B.,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine,
Mintzer, Jacobo E.,
Porsteinsson, Anton P.,
Schneider, Lon S.,
Rabins, Peter V.,
Munro, Cynthia A.,
Meinert, Curtis L.,
Lyketsos, Constantine G.
Background: Depression and antidepressant use are common in Alzheimer disease (AD), but the effect of antidepressant treatment for depression on longer term outcomes is unknown. The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD.; Methods: One hundred thirty-one participants (sertraline = 67, placebo […]